Jenken Biosciences is a specialty pharmaceutical company dedicated to the development and commercialization of first-in-class small molecules as TLR4 antagonists. TLR4 (Toll-Like Receptor 4) is a transmembrane protein, a key mediator of inflammatory responses, and a member of TLR family which are mainstays of the innate immune system. Recently, TLR4 has attracted considerable clinical attention and is the subject of a number of published studies on inflammation associated with chronic liver disease, inflammatory bowel disease, cancer, and diabetes, as well as organ damage to the kidney and lung.

The Company’s drug development strategy is to reduce time-to-market and to lower risk and development costs by re-profiling approved drugs. In addition, the company is developing a rich pipeline of novel chemical entities (NCEs) for therapies of chronic liver disease, inflammatory bowel disease, rheumatoid arthritis, and diabetes, as well as organ damage to the kidney and the lung.